June 21, 2017
Brazilian trial reports positive results for Stalosan® F for swine
Stalosan® F is a familiar product in Denmark, but in new markets, Stalosan is tested to demonstrate its value.
Independent Brazilian trials with strategic use of Stalosan in the farrowing house show interesting results. These results were presented at a newly held Stalosan-seminar in Bangkok immediately after VIV Asia.
The overall conclusion was:
• Increased weaning weight
• Lower frequency of diarrhoea
• Lower piglet mortality
• Reduced costs for medication
The trial, which was conducted in a herd with 400 sows in an integrated production, was designed to document the value of using Stalosan. In the actual trial 142 sows participated with 71 in the control group and 71 in the trial group respectively.
The production results of the herd in 2016 were on average 31.2 weaned pigs per year sow. Weaning took place at 21 days.
The health-related challenges in the herd were M. hyopneumoniae, circovirus, S. suis and H. parasuis.
ROI was 1: 5.4 and that must be said to be a satisfactory financial result under Brazilian conditions.
Strategic use of Stalosan provides some documented possibilities to increase productivity in the herds, primarily by boosting health and reducing the infection pressure.